PHILADELPHIA, September 29, 2022: Morgan Lewis advised Idera Pharmaceuticals, Inc. in the completion of its acquisition of Aceragen, Inc., a privately held, late-stage rare disease biotechnology company. Structured as a stock-for-stock transaction, the combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline through important 2023 clinical milestones.
The Morgan Lewis team advising Idera was led by partners Michael Baxter and Richard Aldridge and associate Richard Umbrecht.